Parker Waichman LLP

FDA Launches Gilenya Safety Review Following Patient Death

The U.S. Food & Drug Administration (FDA) is launching a Gilenya safety review after having recently receiving a report of a patient with multiple sclerosis (MS) who died within 24 hours of taking his/her first dose of Gilenya (fingolimod). The patient died on November 23. Gilenya is a 0.5 mg oral capsule prescribed for the […]

The U.S. Food & Drug Administration (FDA) is launching a Gilenya safety review after having recently receiving a report of a patient with multiple sclerosis (MS) who died within 24 hours of taking his/her first dose of Gilenya (fingolimod). The patient died on November 23.

Gilenya is a 0.5 mg oral capsule prescribed for the treatment of relapsing forms of MS in adults and is used to reduce the frequency of flare-ups (clinical exacerbations) and delay physical disability. Gilenya is the first pill approved by the FDA for the treatment of MS, a devastating neurological disease.

The FDA said it is unable to conclude whether Gilenya, manufactured by Novartis AG, caused the patient’s death but continues to evaluate the case. The agency also said that it believes that Gilenya provides an important health benefit when used as directed and recommends that healthcare professionals who prescribe Gilenya follow the recommendations in the approved drug label. The FDA also said that patients with MS should not stop taking Gilenya without speaking with their healthcare professional.

Gilenya may cause serious side effects that include bradycardia (slow heart rate), which may be related to slowed conduction of electrical impulses from the heart’s upper chambers to its lower chambers. These effects generally do not manifest with symptoms; however, when they do, patients can experiences dizziness, fatigue, and palpitations. Typically, heart rate slowing as a result of taking Gilenya usually happens after the first dose, with the heart rate returning to normal within one month.

Erick Althoff, a Novartis AG spokesman, said in a prior email to Bloomberg News that Gilenya’s involvement in the patient’s death can neither be excluded nor confirmed. This fatality is the first reported death that has occurred within 24 hours of a patient taking his/her first dose of Gilenya, said Althoff, who added that 28,000 patients take Gilenya.

Gilenya was approved in the U.S. in 2010 and was cleared to be sold in Europe earlier this year and is one of several products that Novartis is hoping will increase sales as patents on other Novartis drugs begin to expire, including some key medications. “In the case of MS drugs, there is often significant safety baggage of different sorts,” Tim Anderson, an analyst for Sanford C. Bernstein Ltd., wrote in a note to investors, said Bloomberg News previously.

The patient’s specific cause of the death has not yet been determined, said Novartis; however, sudden death “smacks of being cardiovascular in nature,” wrote Anderson, said Bloomberg News. Anderson added that the potential for a temporary slowdown in heart rate after patients begin Gilenya treatment is one reason a recommendation is called for to monitor Gilenya patients in a doctor’s office as soon as treatment begins.

The patient who died started treatment November 22 and was monitored “without incident” for six hours following the first dose. Novartis said it provided the case’s details to the FDA and other regulatory authorities.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
It was great an professional experience! Really i recomend.
Santiago Lopez
4 months ago
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness Like to say thank you Joonho Hong and Meredith Ippolito. It was such a pleasure to have them on my case. They made sure to keep me updated and corrected any errors from the courts that was done during the time the court was close in this pandemic. They fought for me. I highly recommend Parker Waichman.
Renee Francis
2 years ago
5 Star Reviews 150
PW’s nurse Joanne has been very attentive and supporting since my case has been initiated.
Tiff K
5 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038